Lyme Disease Diagnostic Devices Market Size | Share and Trends 2024 to 2034

Lyme Disease Diagnostic Devices Market Size and Forecast 2024 to 2034

The global lyme disease diagnostic devices market size accounted for USD 2.67 billion in 2024 and is expected to reach around USD 4.56 billion by 2034, expanding at a CAGR of 5.5% from 2024 to 2034. The North America lyme disease diagnostic devices market size reached USD 1.01 billion in 2023.

Lyme Disease Diagnostic Devices Market Key Takeaways

• North America led the global market with the largest market share of 40% in 2023.
• By Product, the serological test segment has held the largest revenue share in 2023.
• By Product, the lymphocytic transformation tests segment is anticipated to expand at a significant CAGR during the projected period.
• By End User, the hospitals segment has held the largest revenue share in 2023.

U.S. Lyme Disease Diagnostic Devices Market Size and Growth 2024 to 2034

The U.S. lyme disease diagnostic devices market size was estimated at USD 710 million in 2023 and is predicted to be worth around USD 1,310 million by 2034, at a CAGR of 5.7% from 2024 to 2034.

North America is Estimated to be the Largest Market for Lyme Disease Diagnostic Devices

The research report covers key trends and prospects of Lyme disease diagnostic devices products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, Lyme disease diagnostic devices market is conquered by North America owing to high incidence of Lyme disease and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing research and development investment by major market players and increasing awareness regarding tick-borne infectious disorders.

Market Overview

Upsurge in incidence of Lyme disease, growing policy attention on improving health care services, and the advent of new diagnostic tests for Lyme disease pushes the market. Nonetheless, lack of knowledge of the disease and ineffectiveness in Lyme disease research reduces the market. Additionally, growth in key players’ interests in Lyme disease diagnosis R&D is predicted to provide lucrative business growth opportunities. Moreover, increasing number of cases of tick-borne infectious diseases is boosting Lyme disease diagnostics market. Vector-borne diseases are illnesses caused by pathogens and parasites in human inhabitants. Each year greater than 1 billion individuals are infected and higher than 1 million people die from vector-borne illnesses. They can be infected by bacteria, parasites or viruses. More than 16% of the ailment and disability endured globally is because of vector-borne illnesses, with more than 50% of world’s population presently assessed to be at risk of these ailments.

Lyme Disease Diagnostic Devices Market Growth Factors

• Growing prevalence of Lyme disease
• Increasing number of cases of tick-borne infectious diseases
• Growing investment in research and development
• Technological advancement
  

Market Scope 

Product Insights

Serological Test Segment Reported Foremost Market Stake in 2023

Serological test segment recorded the prime market share in the global Lyme disease diagnostic devices market by type in 2023. Increasing use in the early diagnosis of Lyme disease diagnostics is the major reason for high market share of serological test. Other factors such as increasing investment in research and development is expected to increase the usage of serological tests over the estimate period.

The lymphocytic transformation tests are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

End User Insights

Hospitals are Projected to Dominate the End User Segment of Lyme Disease Diagnostic Devices Market Revenue

The Lyme disease diagnosis is based on infection signs and symptoms, history of exposures to infected black-legged ticks, and laboratory tests. Serological tests can take several weeks to become conclusive after infection, indicating the need for new diagnostic tests that can identify the earliest signs of infection. Hospitals are well-equipped to handle patient flow and employ latest diagnostic and treatment techniques. These factors are primarily responsible for the greater market share of hospitals in the end-user segment of the Lyme Disease Diagnostic Devices Market.

Public/private laboratories segment will expand at a significant CAGR during the forecast time-frame.

Lyme Disease Diagnostic Devices Market Companies

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Boulder Diagnostics
• T2 Biosystems, Inc.
• Abbott
• Oxford Immunotec Global PLC
• Quidel Corporation
• Affymetrix Inc.
• Hoffmann-La Roche Ltd
• Graphene Frontiers

Major Market Segments Covered

By Product Type

• Serological Test
• Urine Antigen Tests
• Lymphocytic Transformation Test
• Immunofluorescent Staining
• Nucleic acid Test

By End User

• Hospitals
• Public/Private Laboratories
• Physician’s Office

By Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa